secwatch / observer
8-K filed November 9, 2022, 6:59 PM ET ticker WHWK CIK 0001422142
leadership confidence high sentiment neutral materiality 0.75

Aadi Bioscience Q3 revenue $4.2M; Desai to Executive Chairman, Delaney named CEO

Whitehawk Therapeutics, Inc.

item 2.02item 9.01item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brendan Delaney

Director
WHWK · Whitehawk Therapeutics, Inc.
Effective
2023-01-01
Filed
November 9, 2022, 6:59 PM ET
the Board increased the Board’s size from seven (7) to eight (8) directors and elected Mr. Delaney to fill the resulting vacancy, effective as of the Effective Date.
Role change

Brendan Delaney

President and Chief Executive Officer
WHWK · Whitehawk Therapeutics, Inc.
Effective
2023-01-01
Filed
November 9, 2022, 6:59 PM ET
and Brendan Delaney, Chief Operating Officer, to President and Chief Executive Officer of the Company, effective as of January 1, 2023
Role change

Neil Desai

Executive Chairman
WHWK · Whitehawk Therapeutics, Inc.
Effective
2023-01-01
Successor
Brendan Delaney
Filed
November 9, 2022, 6:59 PM ET
the appointment of Neil Desai, founder, director, President and Chief Executive Officer of the Company, to Executive Chairman of the Company

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Whitehawk Therapeutics, Inc. reported the third quarter of 2022 results: revenue $4.2 million, net income Net loss for the three months ended September 30, 2022 was $14.5 million.

Period
the third quarter of 2022
Revenue
$4.2 million
Net income
Net loss for the three months ended September 30, 2022 was $14.5 million
Result
reported results
Exact text from the filing
data in the first half of 2023. • Grew FYARRO net product sales . For the three months ended September 30, 2022, net product sales of FYARRO showed continued growth, ending with $4.2 million in sales in the third quarter, a 24% increase over the second quarter. • Leadership transition. Current CEO, Dr. Neil Desai, has been appointed Executive Chairman,
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan Delaney was elected as Director at Whitehawk Therapeutics, Inc..

Action
elected
Role
Director
Exact text from the filing
the Board increased the Board’s size from seven (7) to eight (8) directors and elected Mr. Delaney to fill the resulting vacancy, effective as of the Effective Date.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Brendan Delaney was appointed as President and Chief Executive Officer at Whitehawk Therapeutics, Inc..

Action
appointed
Role
President and Chief Executive Officer
Exact text from the filing
and Brendan Delaney, Chief Operating Officer, to President and Chief Executive Officer of the Company, effective as of January 1, 2023
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Neil Desai was appointed as Executive Chairman at Whitehawk Therapeutics, Inc..

Action
appointed
Role
Executive Chairman
Exact text from the filing
the appointment of Neil Desai, founder, director, President and Chief Executive Officer of the Company, to Executive Chairman of the Company
View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-22-280757
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.